Weave is a vertical software platform for small and midsized healthcare practices, combining patient communications, workflow tools, and payments while expanding into AI-powered products. The company agreed on August 18, 2026 to be acquired by Francisco Partners for $7.40 per share in cash, so this filing advances an already-public take-private process rather than changing the underlying business strategy.
One regulatory condition is now cleared. Early termination of the U.S. antitrust waiting period removes a required closing hurdle. 〔0〕
The milestone is procedural, not a better deal. The filing says HSR clearance satisfies only one closing condition; Weave still needs stockholder approval and other customary conditions. 〔1〕 Because the acquisition itself was announced on August 18, the direction was already known; the new information is that the transaction has passed one expected regulatory checkpoint.
The timetable remains broadly intact. Management continues to target closing in the fourth quarter of 2026, but does not provide a definitive closing date. 〔2〕
Bottom line: This is clean progress for the announced acquisition, but not a change to its economics or strategic rationale. It reduces execution risk modestly while leaving the shareholder vote as the next meaningful gate. citeturn0search0turn0search5
Read the original 8-K on SEC EDGAR ↗